Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JENNEFER C SUTTON

Allopathic & Osteopathic Physicians Family Medicine

NPI
1790776276
CMS profile
35506
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$137.60

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $137.60 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $118.52 1
Organon LLC $19.08 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JENNEFER C SUTTON

NPI 1790776276 · CMS profile ID 35506

Allopathic & Osteopathic Physicians / Family Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790776276?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JENNEFER C SUTTON, NPI 1790776276, CMS profile ID 35506. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790776276?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JENNEFER C SUTTON, NPI 1790776276, CMS profile ID 35506. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790776276?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JENNEFER C SUTTON, NPI 1790776276, CMS profile ID 35506, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1790776276?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $137.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $118.5202/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002105183 CMS
Organon LLC $19.0802/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046796385 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $25.00 1
PY2023 $137.60 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $10,213.20 3
PY2024 Principal investigator $25,917.10 4
PY2023 Principal investigator $79,360.24 21
PY2022 Principal investigator $137,134.84 242
PY2021 Principal investigator $139,829.55 300
PY2020 Principal investigator $92,369.23 83
PY2019 Principal investigator $165,436.14 99

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

242 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $4,738.50 12/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897226189
Principal investigator 1 ABBVIE INC. $330.75 12/08/2022 Non-covered Recipient Entity
VIP TRIALS
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890369369
Principal investigator 1 Novo Nordisk AS $5,005.80 11/30/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 896945987
Principal investigator 1 Novo Nordisk AS $10,500.00 10/24/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897171079
Principal investigator 1 Novo Nordisk AS $2,928.15 10/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897253579
Principal investigator 1 Novo Nordisk AS $5,378.80 09/28/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 896947233
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 09/19/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947290405
Principal investigator 1 ABBVIE INC. $1,829.25 09/07/2022 Non-covered Recipient Entity
VIP TRIALS
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890366025
Principal investigator 1 Novo Nordisk AS $23.06 09/07/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897273407
Principal investigator 1 Novo Nordisk AS $4,052.02 08/22/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897027441
Principal investigator 1 Esperion Therapeutics, Inc. $1,429.00 08/19/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947286127
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 08/19/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947286133
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 08/19/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947286139
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 08/19/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947286145
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 08/19/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947286151
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 08/19/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947286157
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896957055
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896957305
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896957447
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896957451
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896957454
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896998721
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896999793
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896999797
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896999801
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896999805
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896999809
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896999813
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 896999817
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897023911
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897023915
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897023919
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897023924
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897023927
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897023931
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897023935
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897072799
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897072849
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897072858
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897072862
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897072867
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897072871
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897072874
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897074449
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897074559
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897074567
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897074575
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897074579
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897074583
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897074587
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897074591
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897074595
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897074693
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897114895
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897120437
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897120611
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897120729
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897120731
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897120735
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897120749
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897120836
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897121495
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897121499
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897121503
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897121507
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897121511
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897121515
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897121521
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897121549
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897122315
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897124723
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897124727
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897124731
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897124735
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126655
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126659
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126741
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126745
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126747
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126753
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126757
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126761
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126765
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126769
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126772
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126776
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897126779
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897128381
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897171075
Principal investigator 1 Novo Nordisk AS $9.74 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897171083
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897171087
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897171091
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897171095
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897171099
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897228419
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897228423
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897228427
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897228431
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897228435
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897228439
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897228443
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897228473
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897230009
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897252981
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897252984
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897252987
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897252991
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897252995
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897253001
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897253017
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897253021
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897253025
Principal investigator 1 Novo Nordisk AS $6.50 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897253073
Principal investigator 1 Novo Nordisk AS $7.82 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897253253
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897275597
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897275769
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897275773
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897275777
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897275781
Principal investigator 1 Novo Nordisk AS $8.00 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897275785
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897275793
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897275801
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897275985
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897277965
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897277969
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897277973
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897277977
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897277981
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897277985
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897277989
Principal investigator 1 Novo Nordisk AS $1.08 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897278049
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897293519
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897293523
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897293527
Principal investigator 1 Novo Nordisk AS $5.70 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897293531
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897293535
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897293539
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897293543
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897293547
Principal investigator 1 Novo Nordisk AS $39.90 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897293559
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897293563
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897295253
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897296853
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897296857
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897296861
Principal investigator 1 Novo Nordisk AS $2.75 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897296865
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897296869
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897296873
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897296877
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897296881
Principal investigator 1 Novo Nordisk AS $3.05 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897296883
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897296889
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897306137
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897306139
Principal investigator 1 Novo Nordisk AS $2.95 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897306141
Principal investigator 1 Novo Nordisk AS $40.00 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897306143
Principal investigator 1 Novo Nordisk AS $9.98 08/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9535-4801 No dispute reported 06/30/2026 897306145
Principal investigator 1 Novo Nordisk AS $7,454.02 07/27/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897253575
Principal investigator 1 Novo Nordisk AS $46.12 07/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897273403
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 07/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947280593
Principal investigator 1 Esperion Therapeutics, Inc. $1,429.00 07/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947280599
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 07/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947280605
Principal investigator 1 Esperion Therapeutics, Inc. $1,429.00 07/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947280609
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 07/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947280615
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 07/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947280621
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 07/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947280625
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 07/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947280633
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 07/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947280639
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 07/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947280645
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 07/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947280651
Principal investigator 1 ABBVIE INC. $2,500.00 07/19/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889801583
Principal investigator 1 ABBVIE INC. $4,820.00 07/15/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 889801307
Principal investigator 1 Novo Nordisk AS $23.06 07/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897229129
Principal investigator 1 Novo Nordisk AS $70.00 06/30/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 896867367
Principal investigator 1 Novo Nordisk AS $4,762.80 06/30/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897040823
Principal investigator 1 Esperion Therapeutics, Inc. $1,429.00 06/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947272211
Principal investigator 1 Esperion Therapeutics, Inc. $1,429.00 06/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947272217
Principal investigator 1 Esperion Therapeutics, Inc. $1,429.00 06/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947272223
Principal investigator 1 Esperion Therapeutics, Inc. $1,429.00 06/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947272229
Principal investigator 1 Esperion Therapeutics, Inc. $1,429.00 06/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947272235
Principal investigator 1 Esperion Therapeutics, Inc. $1,429.00 06/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947272241
Principal investigator 1 Esperion Therapeutics, Inc. $1,429.00 06/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947272247
Principal investigator 1 Esperion Therapeutics, Inc. $1,429.00 06/21/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947272253
Principal investigator 1 Novo Nordisk AS $23.06 06/14/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 896945995
Principal investigator 1 Novo Nordisk AS $23.06 06/09/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897037273
Principal investigator 1 Novo Nordisk AS $23.06 06/08/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 896867379
Principal investigator 1 Novo Nordisk AS $23.06 06/07/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897007649
Principal investigator 1 Novo Nordisk AS $23.06 06/01/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897037269
Principal investigator 1 Novo Nordisk AS $70.00 05/31/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 896948543
Principal investigator 1 Novo Nordisk AS $6,296.13 05/27/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897040821
Principal investigator 1 ABBVIE INC. $3,199.95 05/24/2022 Non-covered Recipient Entity
VIP TRIALS LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890363295
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 05/20/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262599
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 05/20/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262605
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 05/20/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262611
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 05/20/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262617
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 05/20/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262621
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 05/20/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262627
Principal investigator 1 Esperion Therapeutics, Inc. $389.00 05/20/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262633
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 05/20/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262639
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 05/20/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262645
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 05/20/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262651
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 05/20/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262657
Principal investigator 1 Novo Nordisk AS $23.06 05/11/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 896867375
Principal investigator 1 Novo Nordisk AS $70.00 04/29/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897040807
Principal investigator 1 Novo Nordisk AS $4,935.33 04/29/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897040816
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 04/22/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947261645
Principal investigator 1 Novo Nordisk AS $46.12 04/18/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897190249
Principal investigator 1 ABBVIE INC. $1,241.10 04/14/2022 Non-covered Recipient Entity
VIP TRIALS
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890362227
Principal investigator 1 ABBVIE INC. $993.45 04/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890362145
Principal investigator 1 ABBVIE INC. $3,792.60 04/12/2022 Non-covered Recipient Entity
VIP TRIALS LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890362229
Principal investigator 1 Novo Nordisk AS $23.06 04/05/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897007643
Principal investigator 1 Novo Nordisk AS $70.00 03/31/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897027437
Principal investigator 1 Novo Nordisk AS $1,000.00 03/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 896867371
Principal investigator 1 Novo Nordisk AS $9,332.41 03/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 896945991
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 03/22/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257307
Principal investigator 1 Esperion Therapeutics, Inc. $389.00 03/22/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257317
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/22/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257327
Principal investigator 1 ABBVIE INC. $894.40 03/17/2022 Non-covered Recipient Entity
VIP TRIALS
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890361829
Principal investigator 1 Novo Nordisk AS $23.06 03/03/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897037261
Principal investigator 1 Novo Nordisk AS $23.06 03/02/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 896867363
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/01/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947253839
Principal investigator 1 Esperion Therapeutics, Inc. $966.00 03/01/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947253945
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 03/01/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947253951
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/01/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947253957
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/01/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947253963
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/01/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947254051
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 03/01/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947254057
Principal investigator 1 Novo Nordisk AS $23.06 03/01/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897011051
Principal investigator 1 Novo Nordisk AS $70.00 02/28/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897037265
Principal investigator 1 Novo Nordisk AS $6,252.39 02/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 896948551
Principal investigator 1 ABBVIE INC. $1,830.15 02/16/2022 Non-covered Recipient Entity
VIP TRIALS
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 889777411
Principal investigator 1 Novo Nordisk AS $9,715.14 02/07/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897027445
Principal investigator 1 Novo Nordisk AS $25.06 02/02/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897027449
Principal investigator 1 Novo Nordisk AS $70.00 01/31/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 896948671
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 01/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947247645
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 01/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947247651
Principal investigator 1 Esperion Therapeutics, Inc. $664.00 01/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947247657
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 01/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947247663
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 01/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947248387
Principal investigator 1 Esperion Therapeutics, Inc. $234.00 01/25/2022 Non-covered Recipient Entity
VIP TRIALS LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947248463
Principal investigator 1 ABBVIE INC. $661.50 01/13/2022 Non-covered Recipient Entity
VIP TRIALS
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 889773907
Principal investigator 1 Novo Nordisk AS $25.06 01/05/2022 Non-covered Recipient Entity
VIP TRIALS LLC
NN9924-4635 No dispute reported 06/30/2026 897040811